Greenland Mines Ltd. Common Stock (GRML)

FairStock Score: 32/100 — RISKY

Key Financials

AI Analysis

AI-generated, general educational analysis — not personal investment advice.

Greenland Mines is not a business I can underwrite with confidence. It calls itself a natural-resources explorer in palladium, gold, platinum, and rare earths, while also developing a cell-and-gene-therapy asset, and it has only 5 employees. The filed figures show revenue n/a for every period listed, so there is no operating revenue to judge. In fiscal 2025, ended 2025-12-31, net income was -$10.6 million and diluted EPS was -$0.22. The quarter ended 2026-06-30 lost -$3.7 million, and the quarter ended 2026-03-31 lost -$13.9 million. Trailing free cash flow is -$16.1 million, and the FCF yield is -1.8%. Financial health has one bright spot: debt is negligible, D/E 0.01, and the Altman Z-Score is 73.64. But Piotroski is 1/9, ROE is -63.84%, and ROCE is -30.76%. Those are not the marks of durable earning power or a moat. At the close on 2026-10-13, the price is $5.54, market cap is $880.0 million, FairStock's P/E is -30.78, and P/B is 15.39. That is a rich price for a no-revenue, cash-burning explorer and therapy hopeful. FairStock lists profit growth of 9.97%, but with no revenue and continuing losses, I see speculation, not a margin of safety.

In plain English: Greenland Mines explores metals in Greenland and is also working on a gene therapy. Its filed reports show no revenue and ongoing losses, so the business looks weak. At the 2026-10-13 close of $5.54, the shares look expensive compared with those numbers.

The full AI analysis, bull and bear case and key monitorables are in FairStock Pro.

Data as of 2026-10-13 close · note generated 2026-10-15 · model deepseek-flash

Sources (SEC EDGAR): fiscal Q2 2026 10-Q (period ended 2026-06-30) · fiscal Q1 2026 10-Q (period ended 2026-03-31) · fiscal Q3 2025 10-Q (period ended 2025-09-30) · fiscal Q2 2025 10-Q (period ended 2025-06-30) · FY2025 10-K/A (period ended 2025-12-31) · FY2024 10-K/A (period ended 2024-12-31) · FY2023 10-K (period ended 2023-12-31)

Fundamentals from company filings and market-data providers; prices are end-of-day, not real-time. AI-generated analysis is general and educational — not personal investment advice. Scoring methodology · Score test · Disclaimer